Endoscopic submucosal dissection (ESD) has emerged as a highly effective and safe treatment for high-risk colorectal colitis-associated neoplasia (HR-CAN) in patients with inflammatory bowel disease (IBD), according to a multicenter Italian study. HR-CAN in IBD patients, particularly those with long-standing ulcerative colitis or colonic Crohn's disease, poses a significant risk for colorectal cancer and presents unique challenges due to chronic inflammation, scarring, and altered anatomy.
Endoscopic submucosal dissection (ESD) has emerged as a highly effective and safe treatment for high-risk colorectal colitis-associated neoplasia (HR-CAN) in patients with inflammatory bowel disease (IBD), according to a multicenter Italian study. HR-CAN in IBD patients, particularly those with long-standing ulcerative colitis or colonic Crohn's disease, poses a significant risk for colorectal cancer and presents unique challenges due to chronic inflammation, scarring, and altered anatomy.
The study included 91 IBD patients with 96 HR-CAN lesions, with an average lesion size of 35 mm. Most lesions exhibited high-grade dysplasia or early adenocarcinoma. Conventional ESD was performed in 82% of cases, while 18% underwent hybrid ESD (hESD). Despite the complexity of the lesions, the outcomes were excellent. En bloc resection (complete removal of the lesion in one piece) was achieved in 95.8% of cases, and R0 resection (clear margins) was successful in 85.4%. Curative resection, meaning no further surgery was needed, was achieved in 83.3% of patients.
Adverse events were low (12.5%) and managed non-invasively. During a mean follow-up of two years, local recurrence and metachronous lesion rates were only 3.1% each, showing durable outcomes. Approximately 11.5% of patients required surgery post-resection, often for reasons unrelated to ESD.
This study underscores that ESD is a highly promising, minimally invasive option for managing HR-CAN in IBD patients, providing strong long-term outcomes, low recurrence rates, and reduced need for surgical interventions.
Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...
Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...
Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...
Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...
Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.